Disease · MONDO_0100280
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Ibrutinib vs Arm B: Zanubrutinib: deaths from any cause | 19 of 99 | 14 of 102 | 201 | NCT03053440 | Trial comparisons |
| Arm A: Ibrutinib vs Arm B: Zanubrutinib: serious adverse events | 50 of 98 | 59 of 101 | 199 | NCT03053440 | Trial comparisons |
| Multiple Myeloma (MM) vs Waldenstrom's Macroglobulinemia (WM): Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment | 0 of 14 | 1 of 42 | 56 | NCT00718419 | Trial comparisons |
| Multiple Myeloma (MM) vs Waldenstrom's Macroglobulinemia (WM): serious adverse events | 4 of 14 | 9 of 42 | 56 | NCT00718419 | Trial comparisons |
300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5 vs 300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5: Number of Participants With OR for Cycle 1 (Excluding the Redosing Cycle), as Assessed by the Investigator | 5 of 15 | 14 of 22 | 37 | NCT00811733 | Trial comparisons |
300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5 vs 300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5: Number of Participants With Overall Response (OR) for Cycle 1 (Including the Redosing Cycle), as Assessed by the Investigator | 7 of 15 | 15 of 22 | 37 | NCT00811733 | Trial comparisons |
| 300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5 vs 300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5: serious adverse events | 5 of 15 | 7 of 22 | 37 | NCT00811733 | Trial comparisons |
300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5 vs 300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5: Number of Participants With at Least One Confirmed Positive Post-ofatumumab HAHA Result | 1 of 11 | 4 of 20 | 31 | NCT00811733 | Trial comparisons |
| MYD88 Mutated, CXCR4 Wild-type vs MYD88 Mutated, CXCR4 Mutated: Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status | 11 of 11 | 14 of 15 | 26 | NCT02400437 | Trial comparisons |
| MZL: Umbralisib vs WM: Umbralisib: Number of Participants With at Least One Adverse Event (AE) | 8 of 8 | 13 of 13 | 21 | NCT03364231 | Trial comparisons |
| MZL: Umbralisib vs WM: Umbralisib: deaths from any cause | 1 of 8 | 0 of 13 | 21 | NCT03364231 | Trial comparisons |
| MZL: Umbralisib vs WM: Umbralisib: serious adverse events | 1 of 8 | 0 of 13 | 21 | NCT03364231 | Trial comparisons |
| Cohort 2 vs Cohort 3: Number of Patients Experiencing MTD | 1 of 3 | 5 of 6 | 9 | NCT01198067 | Trial comparisons |
| Cohort 2 vs Cohort 3: deaths from any cause | 0 of 3 | 0 of 6 | 9 | NCT01198067 | Trial comparisons |
| Cohort 2 vs Cohort 3: serious adverse events | 3 of 3 | 1 of 6 | 9 | NCT01198067 | Trial comparisons |
| Arm A (Phase I: Temsirolimus Dose Level 1, Rituximab, Bortezomib, Dexamethasone) vs Arm B (Phase I: Temsirolimus Dose Level 2, Rituximab, Bortezomib, Dexamethasone): deaths from any cause | 1 of 7 | 0 of 2 | 9 | NCT01381692 | Trial comparisons |
| Arm A (Phase I: Temsirolimus Dose Level 1, Rituximab, Bortezomib, Dexamethasone) vs Arm B (Phase I: Temsirolimus Dose Level 2, Rituximab, Bortezomib, Dexamethasone): serious adverse events | 7 of 7 | 1 of 2 | 9 | NCT01381692 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100280/comparisons